Article

Management of ocular inflammation and pain using novel insert

Author(s):

Julianne Mobilian
Conferences|ASCRS

ICMYI: Dr. Tyson shares his pearls using the dexamethasone 0.4 mg insert (Dextenza, Ocular Therapeutix).

Sydney Tyson, MD, shares the take-home message from the presentation he delivered at the 2019 American Society of Cataract and Refractive Surgery meeting: "Management of Ocular Inflammation and Pain Following Cataract Surgery with Dexamethasone 0.4 mg Insert (Dextenza, Ocular Therapeutix)."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Related Content
Q&A: Continuum of care, the evolution of cornea, cataract, and refractive surgery
April 26th 2025

Q&A: Continuum of care, the evolution of cornea, cataract, and refractive surgery

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

(Image credit: AdobeStock/Anton Gvozdikov)
April 22nd 2025

When the world went virtual: How ophthalmology’s conferences stayed on track

EyePod: Integrating cutting-edge pipeline devices for enhanced cataract surgery
December 19th 2023

EyePod: Integrating cutting-edge pipeline devices for enhanced cataract surgery

A woman is seen with a red eye and a hand with a blue glove
March 27th 2025

Fine-tuning the treatment of postoperative endophthalmitis

ZEISS VISULAS Combi availability expands to Canada
March 24th 2025

ZEISS VISULAS Combi availability expands to Canada

© 2025 MJH Life Sciences

All rights reserved.